Hungarian veterinary drug company Phylaxia raised company capital through a private placement of 14 million new shares, Phylaxia reported on Tuesday evening.
Existing shareholders purchased 7,280,000 new Phylaxia shares, while Kálmán Böjthe, a Hungarian living in Germany, purchased 6,720,000 company shares, Phylaxia said on Tuesday.
The issue price was 100% of the shares , which have a nominal value of HUF 25 million each. The transaction was underwritten by Kálmán Böjthe, with the option for existing shareholders to exercise their preemption right.
Phylaxia announced on July 27 that the company’s board had decided to raise capital by HUF 350 million to HUF 1.444 billion through the issue of the shares by August 11.
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
